PDSB (PDS Biotechnology) 12-1 Month Momentum % : -41.85% (As of Dec. 13, 2024)

View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-12-13), PDS Biotechnology's 12-1 Month Momentum % is -41.85%.

The industry rank for PDS Biotechnology's 12-1 Month Momentum % or its related term are showing as below:

PDSB's 12-1 Month Momentum % is ranked worse than
75.09% of 1445 companies
in the Biotechnology industry
Industry Median: -13.2 vs PDSB: -41.85

Competitive Comparison of PDS Biotechnology's 12-1 Month Momentum %

For the Biotechnology subindustry, PDS Biotechnology's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PDS Biotechnology's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PDS Biotechnology's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where PDS Biotechnology's 12-1 Month Momentum % falls into.

PDS Biotechnology (NAS:PDSB) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology (NAS:PDSB) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

PDS Biotechnology 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

PDS Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

EU6:Germany

Address

303A College Road, East Princeton, NJ, USA, 08540

Website

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Executives

Spencer D. Brown	officer: Senior VP, General Counsel	25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill	officer: Chief Financial Officer	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist	director, 10 percent owner	RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson	director	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King	officer: Interim Chief Financial Office	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev	director	303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk	officer: Principal Accounting Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes	director	C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo	director, 10 percent owner, officer: President/CEO	300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood	officer: Chief Medical Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn	officer: Chief Scientific Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922